trending Market Intelligence /marketintelligence/en/news-insights/trending/z1r9xlzv-utkccbyltlrcw2 content esgSubNav
In This List

Fennec drug secures another US FDA designation

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Fennec drug secures another US FDA designation

Fennec Pharmaceuticals Inc. secured the U.S. Food and Drug Administration's breakthrough therapy status for its drug Pedmark.

Pedmark prevents ototoxicity, or ear damage, as a side-effect of cisplatin chemotherapy in children with standard-risk hepatoblastoma. Hepatoblastoma is a very rare cancerous tumor that starts in the liver and primarily affects children.

The therapy previously received the FDA's fast track designation. The designation allows the regulator to accelerate the review process for drugs indicated to treat serious and life-threatening conditions.

The breakthrough therapy designation will include all features of the fast track, as well as more intensive FDA guidance on an efficient drug development program.

Research Triangle Park, N.C.-based Fennec is a biopharmaceutical company that develops product candidates for use in the treatment of cancer in the U.S.